Ajer Jeffrey Robert's Form 4 filing
Biomarin Pharmaceutical Inc (BMRN) · filed Mar 31, 2022
- Accession no.
- 0001567619-22-007808
- Filed
- Mar 31, 2022
- Trade date
- Mar 29-30, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $238.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ajer Jeffrey RobertCIK 0001557533 | Officer (EVP, Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 29, 2022 | Common Stock | SSaleDisposed | −1,618 | $79.43 | −$128,517.74 | 57,638 | Direct | |
| Mar 30, 2022 | Common Stock | SSaleDisposed | −1,381 | $79.56 | −$109,872.36 | 56,257 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.